Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database (road031, 2023)

被引：0
|
作者：
Harigai, M.
机构：
来源：
MODERN RHEUMATOLOGY | 2024年 / 34卷 / 02期
关键词：
D O I：
10.1093/mr/road048
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：437 / 437
页数：1
相关论文
共 50 条
  • [31] Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
    Best, Jennie H.
    Vlad, Steven C.
    Tominna, Lenore
    Abbass, Ibrahim
    RHEUMATOLOGY AND THERAPY, 2020, 7 (02) : 345 - 355
  • [32] Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
    Jennie H. Best
    Steven C. Vlad
    Lenore Tominna
    Ibrahim Abbass
    Rheumatology and Therapy, 2020, 7 : 345 - 355
  • [33] Tuberculosis Risk Among Patients with Rheumatoid Arthritis in a United States Claims Database Initiating Abatacept and Other Biologic Disease-Modifying Antirheumatic Drugs: Analyses Using International Classification of Diseases Codes and a Published Claims Algorithm
    Baker, N.
    Suissa, S.
    Kawabata, H.
    Skovron, M.
    Moorthy, V.
    Simon, T. A.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [34] Paradigm guiding to tapering or discontinuation of biologic and targeted synthetic disease-modifying antirheumatic drugs in the treatment of patients with rheumatoid arthritis: Results from a local prospective study
    Kaban, Nedim
    Harman, Halil
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (04) : 689 - 698
  • [35] Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry
    Harigai, Masayoshi
    Tanaka, Eiichi
    Inoue, Eisuke
    Sakai, Ryoko
    Sugitani, Naohiro
    Toyoizumi, Shigeyuki
    Sugiyama, Naonobu
    Yamanaka, Hisashi
    RHEUMATOLOGY AND THERAPY, 2024, 11 (05) : 1181 - 1195
  • [36] Disease-modifying antirheumatic drug selection in Japanese patients with rheumatoid arthritis treated with biologics or JAK inhibitors without methotrexate: A retrospective hospital-based administrative claims database study
    Miyakawa, Naohisa
    Tsuritani, Katsuki
    Teixeira, Bruno Casaes
    Fujio, Keishi
    MODERN RHEUMATOLOGY, 2024, 34 (05) : 900 - 909
  • [37] Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting
    Liang, Huifang
    Danwada, Raghava
    Guo, Dianlin
    Curtis, Jeffrey R.
    Kilpatrick, Ryan D.
    Hendrickson, Barbara
    Islam, Syed S.
    RMD OPEN, 2019, 5 (02):
  • [38] Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies
    Takeuchi, Tsutomu
    Soen, Satoshi
    Ishiguro, Naoki
    Yamanaka, Hisashi
    Tanaka, Sakae
    Kobayashi, Makiko
    Okubo, Naoki
    Nitta, Takaya
    Tanaka, Yoshiya
    MODERN RHEUMATOLOGY, 2021, 31 (01) : 34 - 41
  • [39] Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis
    Sebnem Ataman
    Ismihan Sunar
    Hatice Bodur
    Meltem Alkan Melikoglu
    Hasan Fatih Cay
    Erhan Capkin
    Ozgur Akgul
    Remzi Cevik
    Feride Gogus
    Ayhan Kamanli
    Fatma Gul Yurdakul
    Gulcan Gurer
    Ilker Yagci
    Aylin Rezvani
    Mehmet Tuncay Duruoz
    Rheumatology and Therapy, 2022, 9 : 223 - 241
  • [40] Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis
    Ataman, Sebnem
    Sunar, Ismihan
    Bodur, Hatice
    Melikoglu, Meltem Alkan
    Cay, Hasan Fatih
    Capkin, Erhan
    Akgul, Ozgur
    Cevik, Remzi
    Gogus, Feride
    Kamanli, Ayhan
    Yurdakul, Fatma Gul
    Gurer, Gulcan
    Yagci, Ilker
    Rezvani, Aylin
    Duruoz, Mehmet Tuncay
    RHEUMATOLOGY AND THERAPY, 2022, 9 (01) : 223 - 241
12345